RECRUITINGOBSERVATIONAL
Genomic and Proteomic Analysis of Disease Progression in Idiopathic Pulmonary Fibrosis (IPF)
Genomic and Proteomic Analysis of Disease Progression in Idiopathic Pulmonary Fibrosis
About This Trial
The purpose of the study is to identify genetic and biologic markers that may predict the loss of lung function due to idiopathic pulmonary fibrosis. The studies will compare genetic and biologic markers of samples to changes in symptoms. The ultimate goal is to predict if or when patients are likely to experience a rapid decline in lung function due to disease progression.
Who May Be Eligible (Plain English)
Who May Qualify:
- Patients who are 18 or older
- Diagnosis of Idiopathic Pulmonary Fibrosis
- Treated at the Simmons Center
Who Should NOT Join This Trial:
- Other Lung Illness
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Patients who are 18 or older
* Diagnosis of Idiopathic Pulmonary Fibrosis
* Treated at the Simmons Center
Exclusion Criteria:
* Other Lung Illness
Locations (1)
Michelle F MacPherson
Pittsburgh, Pennsylvania, United States